Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory CD19-positive hematolymphoid malignancies.

Trial Details

NCT ID
NCT07284927
Phase
PHASE1
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • LV009 Injection
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Aged 18 to 70 years (inclusive), irrespective of sex and race.
  • Life expectancy greater than 12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 2.
  • Meets the National Comprehensive Cancer Network (NCCN) criteria for relapsed or refractory disease, with a confirmed diagnosis of CD19-positive hem…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →